SeekingAlpha  Oct 1  Comment 
By Matthew D. McCall: The recent pullback in the U.S. stock market has been viewed from two different lenses. The bears believe it is the start of a significant pullback while the bulls look at it as an opportunity to buy at lower prices. The last...
DailyFinance  Sep 29  Comment 
LYON, FRANCE -- (Marketwired) -- 09/29/14 -- Flamel Technologies (NASDAQ: FLML) today announced the results of a First-in-Man (FIM) clinical study in healthy volunteers using its proprietary LiquiTime® drug delivery platform applied to...
StreetInsider.com  Aug 4  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Flamel+Technologies+%28FLML%29+Updates+on+Unapproved+Neostigmine+Methylsulfate+Manufacturers/9715304.html for the full story.
SeekingAlpha  Jul 29  Comment 
Flamel Technologies SA (NASDAQ:FLML) Q2 2014 Earnings Conference Call July 29, 2014 10:00 PM ET Executives Bob Yedid – ICR Investor Relations Michael S. Anderson – Chief Executive Officer Steven A. Lisi – Senior Vice...
SeekingAlpha  Jul 9  Comment 
By Ronny Hyman: In June, the FDA indicated the neostigmine methylsulfate shortage had been resolved. Recent public evidence that unapproved formulations of neostigmine will no longer be marketed after September 30, 2014 sets the stage for market...
Benzinga  Jun 30  Comment 
MannKind (NASDAQ: MNKD) shares moved up 11.30% to $11.13. The volume of MannKind shares traded was 784% higher than normal. MannKind jumped following the conditional FDA approval for Afrezzaa. Dicerna Pharmaceuticals (NASDAQ: DRNA) shares rose...
Motley Fool  Jun 30  Comment 
MannKind, Dicerna, Flamel, and Merck are the top biotech stocks to watch this Monday morning.
StreetInsider.com  Jun 30  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Flamel+Technologies+%28FLML%29+VAZCULEP+NDA+Approved+by+U.S.+FDA/9622592.html for the full story.



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki